Abstract
Background & Objective: Huntington's disease (HD) is an autosomal-dominant, progressive neurodegenerative disease characterized by selective loss of neurons in the striatum and cortex, which leads to progressive motor dysfunction, cognitive decline and behavioral symptoms. HD is caused by a trinucleotide (CAG) repeat expansion in the gene encoding the protein huntingtin. Despite the fact that the HD gene was identified over 20 years ago, there is no effective disease-modifying therapy for HD and only symptomatic therapies are available to date. Recently, new agents and procedures have been investigated for HD and many of them have focused on immunomodulatory and/or anti- inflammatory strategies.
Conclusion: The objective of the current review is to summarize data on the therapeutic strategies to treat HD that are based on immunomodulatory effects.
Keywords: Huntington's disease, inflammation, treatment, symptomatic therapies, disease modifying treatment, stem cells.
CNS & Neurological Disorders - Drug Targets
Title:Immunomodulatory Strategies for Huntington's Disease Treatment
Volume: 16 Issue: 8
Author(s): Gabriela D. Colpo*, Natalia P. Rocha, Erin Fur Stimming and Antonio L. Teixeira
Affiliation:
- Neuropsychiatry Program, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX,United States
Keywords: Huntington's disease, inflammation, treatment, symptomatic therapies, disease modifying treatment, stem cells.
Abstract: Background & Objective: Huntington's disease (HD) is an autosomal-dominant, progressive neurodegenerative disease characterized by selective loss of neurons in the striatum and cortex, which leads to progressive motor dysfunction, cognitive decline and behavioral symptoms. HD is caused by a trinucleotide (CAG) repeat expansion in the gene encoding the protein huntingtin. Despite the fact that the HD gene was identified over 20 years ago, there is no effective disease-modifying therapy for HD and only symptomatic therapies are available to date. Recently, new agents and procedures have been investigated for HD and many of them have focused on immunomodulatory and/or anti- inflammatory strategies.
Conclusion: The objective of the current review is to summarize data on the therapeutic strategies to treat HD that are based on immunomodulatory effects.
Export Options
About this article
Cite this article as:
Colpo D. Gabriela *, Rocha P. Natalia , Stimming Fur Erin and Teixeira L. Antonio, Immunomodulatory Strategies for Huntington's Disease Treatment, CNS & Neurological Disorders - Drug Targets 2017; 16 (8) . https://dx.doi.org/10.2174/1871527316666170613084801
DOI https://dx.doi.org/10.2174/1871527316666170613084801 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Potential Therapeutics for Schizophrenia: Focus on the Modulation of Metabotropic Glutamate Receptor Function
Current Neuropharmacology Peptides Targeting Toll-Like Receptor Signalling Pathways for Novel Immune Therapeutics
Current Pharmaceutical Design Selective Serotonin-norepinephrine Re-uptake Inhibition Limits Renovas-cular-hypertension Induced Cognitive Impairment, Endothelial Dysfunction, and Oxidative Stress Injury
Current Neurovascular Research Why is the Inhibition of the Renin-Angiotensin System Effective for Preventing Cardiac Events in Patients with Coronary Risk Factors or Coronary Artery Disease?
Current Cardiology Reviews Cannabinoid Receptor Type 2 Activation Yields Delayed Tolerance to Focal Cerebral Ischemia
Current Neurovascular Research In Vivo Experimental Models of Epilepsy
Central Nervous System Agents in Medicinal Chemistry Synthesis and Evaluation of Phenyliminoindolin-Containing Phenylacetamide Derivatives with the Antidepressant and Anticonvulsant Effects
Medicinal Chemistry The Impact of In Vitro Binding on In Vitro - In Vivo Extrapolations, Projections of Metabolic Clearance and Clinical Drug-Drug Interactions
Current Drug Metabolism Is Androstadienone a Putative Human Pheromone?
Current Medicinal Chemistry Nicotine Replacement Therapy During Pregnancy and Lactation Induce Structural and Functional Changes in the Lungs of the Progeny
Current Women`s Health Reviews Patent Selections:
Recent Patents on Food, Nutrition & Agriculture Characterization of Endogenous Neural Progenitor Cells after Experimental Ischemic Stroke
Current Neurovascular Research Editorial (Thematic Issue: Pharmacologic Strategies with Afterload Reduction in Low Cardiac Output Syndrome After Pediatric Cardiac Surgery)
Current Vascular Pharmacology Co-Induction of CYP3A12 and 3A26 in Dog Liver Slices by Xenobiotics: Species Difference Between Human and Dog CYP3A Induction
Drug Metabolism Letters Active Amyloid-β Vaccination Results in Epigenetic Changes in the Hippocampus of an Alzheimer’s Disease-Like Mouse Model
Current Alzheimer Research A Mechanistic Study on Altered Pharmacokinetics of Irinotecan by St. Johns Wort
Current Drug Metabolism Alzheimer's Disease and Diabetes: New Insights and Unifying Therapies
Current Diabetes Reviews Altered Mesolimbic Dopamine System in THC Dependence
Current Neuropharmacology Meet Our Editorial Board Member
Recent Patents on CNS Drug Discovery (Discontinued) Modulatory Effects of Peroxisome Proliferator-Activated Receptor-γ on CXCR3 Chemokines
Recent Patents on Inflammation & Allergy Drug Discovery